US Pharma MarketingFDA places clinical hold on Regenxbio’s RGX-121 in MPS II trial
REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.
REGENXBIO has reported that the US FDA has placed a clinical hold on its investigational gene therapy, RGX-121, developed for the treatment of MPS II.
Source: Pharmaceutical Technology